An interventional study of Breathing exercise in Fibromyalgia, sponsored by Istanbul Medeniyet University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 25 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Istanbul Medeniyet University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 195 studies in Fibromyalgia with a site in Turkey — 50 open to participants now, 54 under way, none of them phase 3. Fibromyalgia · Turkey.
Among the 195 studies in Fibromyalgia with a site in Turkey, this one is the 80th largest by enrollment of the 104 interventional ones that give a count, is one of 28 that started in 2024, is one of 102 with no phase, and was the 109th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →50 of the 195 studies in Fibromyalgia with a site in Turkey are open now. Recruiting first, the newest first:
Karabuk University · Sites in Turkey
Ages 18–65 · Women only · Healthy volunteers
Artvin Coruh University · Sites in Turkey
Ages 18+
Artvin Coruh University · Sites in Turkey
Ages 18+
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ankara Yildirim Beyazıt University · Sites in Turkey
Ages 18–65 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 25 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 28 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 52 across the 104 interventional studies, 100 across the 91 observational. Of the 127 that completed or were terminated, 3 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 195 have an industry lead sponsor. The 10 most frequent:
Istanbul Medeniyet University is the lead sponsor of 193 studies on the registry; 17 are open to participants now.
Istanbul Medeniyet University has 2 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
18 of the studies in Fibromyalgia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07261696Nigde Omer Halisdemir UniversityThe Effects of Inspiratory Muscle Training Female Patients With Fibromyalgia | 2026-12-05 |
| NCT07403929Hacettepe UniversityThe Effect of Fermented Grape Juice Consumption on Fibromyalgia Patients | 2026-12-15 |
| NCT07326163Bilecik Seyh Edebali UniversitesiThe Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients | 2026-12-30 |
| NCT07878286Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyThe Role of Interoceptive Sensitivity in Central Sensitization Symptom Severity in Fibromyalgia | 2027-01-15 |
| NCT07830186Saglik Bilimleri UniversitesiQigong Intervention for Fibromyalgia | 2027-01-21 |
Add all 18 to your calendar (.ics) → With an account.
Among the 195 studies in Fibromyalgia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fibromyalgia (FM) is a chronic pain syndrome characterized by impaired perception, transmission, and processing of nociceptive stimuli and causing widespread pain. Pain in FM is the disease itself and is characterized by nociplastic pain that may occur independently of any peripheral nociceptor activity or be felt without disease or damage to the somatosensory system. It is thought that the pain processing process is disrupted due to the changing neurotransmitter release activity and this situation causes pain to be felt more in FM. Chronic pain is the result of perception alteration associated with nociceptive afferent information affecting the cortex; underlying this change are limbic emotional learning mechanisms. Numerous factors, including emotional state, attention, and past painful experiences, modulate nociceptive inputs with the activation of multiple brain regions, resulting in a personalized pain experience. The chronic pain management program should target the central nervous system rather than the peripheral tissues because pain originates in the sensitized nervous system. For this reason, it is important to include plasticity-oriented approaches, cortical disinhibition methods, and strategies for improving perception and behavior change, which aim to replace negative beliefs with positive beliefs, into clinical practice. Our project aims to investigate the effectiveness of the therapeutic intervention, which consists of patient education supported Neuro-Linguistic Programming (NLP), visual feedback and metaphor-assisted breathing therapy designed to provide a perception of improvement and presented in a virtual reality environment, on pain processing, pain intensity, pain-pressure threshold, psychosomatic reflections (biomechanical and viscoelastic properties of tissue, sleep quality, pain catastrophizing behavior, anxiety and depression), disease impact and quality of life in FM patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with Fibromyalgia at least 1 year ago according to ACR criteria
Age range 25-55
Female
Scored at least 24 on the Mini-Mental State Assessment Test
Reported weekly pain intensity of at least 40 mm on the Visual Analog Scale
Be on a stable dose of medication for at least 6 months (serotonin norepinephrine reuptake inhibitors [e.g., duloxetine, milnacipran]; alpha 2-delta receptor ligand [e.g., pregabalin]; gabapentinoids)
Exclusion Criteria:
Having inflammatory rheumatic disease, , neurological disease, connective tissue disease, severe anemia, uncontrolled endocrine diseases
(BMI) ≥ 30 Kg/m2
Being pregnant
Having inability to understand, read and speak Turkish
Having difficulty in hearing and seeing
Having any metallic or electronic device in the body that will create incompatibility with the magnetic field in the fMRI scan Having any disease diagnosis (serious psychotic disorder, delirium, mental retardation, epilepsy, heart disease, lung diseases, etc.) that may prevent participation in the evaluation and training to be conducted within the scope of the research
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NLP-supported patient education will be given and breath therapy will be applied to the Control Group
Other: Breathing exercise
NLP-supported patient education will be given. Visual feedback and metaphor-assisted breathing therapy over the three most painful points in the McGill-Melzack Pain Scale (real painful points) were given to this group in virtual reality environment.
Other: Breathing exercise
NLP-supported patient education will be given. Visual feedback and metaphor-assisted breathing therapy over the contralateral of the points reported as the three most painful points in the McGill-Melzack Pain Scale (virtual painful points) to this group in a virtual reality environment
Other: Breathing exercise
Breathing exercises will include; 1. Correct posture and sitting 2. Nose opening techniques 3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm 4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds).
Functional Magnetic Resonance
The process of processing pain will be determined by functional magnetic resonance imaging performed immediately before and after the experimental pressure pain. ROI analysis will ve performed. No score is defined.
Time frame: Measurement of changes from baseline process of processing pain will be measured at 6 week and 10 week
Measurement of pain-pressure threshold
Pain-pressure threshold evaluated with a pain threshold measuring device (Algometer).
Time frame: Measurement of changes from baseline of pain-pressure threshold will be measured at 6 week and 10 week
Sleep Quality
Sleep quality will be evaluated with Pittsburgh Sleep Quality Index. Score is between 0 (the best sleep quality) and 21 (the worst sleep quality)
Time frame: Measurement of changes from baseline of sleep quality will be measured at 6 week and 10 week
Functional status and disease impact
Functional status and disease impact will be evaluated with Revised Fibromyalgia Impact Questionnaire. Score is between 0 (no disease impact and 100 (the highest disease impact)
Time frame: Measurement of changes from baseline of functional status and disease impact will be measured at 6 week and 10 week.
Quality of Life of patients
Quality of Life will be measured with QOL Short Form 12. Score is between 0 (the lowest quality of life and 100 (the highest quality of life)
Time frame: Measurement of changes from baseline of quality of life will be measured at 6 week and 10 week
Anxiety and Depression Status
Anxiety and Depression will be evaluated with Hospital Anxiety and Depression Scale. Score is between 0 (no anxiety and depression risk) and 21 (the highest anxiety and depression risk)
Time frame: Measurement of changes from baseline of anxiety and depression status will be measured at 6 week and 10 week
Pain catastrophizing behavior
Assessing pain catastrophizing behavior will be evaluated with Pain Catastrophizing Scale. Score is between 0 (no pain catastrophizing behavior) and 52 (the highest pain catastrophizing behavior)
Time frame: Measurement of changes from baseline of changes from baseline of pain catastrophizing behaviors will be measured at 6 week and 10 week
Patient satisfaction
Patient satisfaction will be evaluated with Global Rating of Change. No score is defined.
Time frame: Measurement of changes from baseline of patient satisfaction will be measured at 6 week and 10 week
Measurement of biomechanical characteristics of tissue
Stiffness values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Stiffness values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.
Time frame: Measurement of changes from baseline stiffness values of tissue will be measured at 6 week and 10 week]
Measurement of biomechanical characteristics of tissue
Tone values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Tone values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.
Time frame: Measurement of changes from baseline tone values of tissue will be measured at 6 week and 10 week]
Measurement of biomechanical characteristics of tissue
Decrement values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Decrement values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.
Time frame: Measurement of changes from baseline decrement values of tissue will be measured at 6 week and 10 week]
Measurement of viscoelastic characteristics of tissue
Creep values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Creep values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.
Time frame: Measurement of changes from baseline creep values of tissue will be measured at 6 week and 10 week]
Measurement of viscoelastic characteristics of tissue
Relaxation time values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Relaxation time values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.
Time frame: Measurement of changes from baseline relaxation time values of tissue will be measured at 6 week and 10 week]
Ran from Aug 2024 to primary completion in Aug 2026, 23 months.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 23 months is above that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Medeniyet University →